Background: Superparamagnetic iron oxide nanoparticles (SPIONs) have been extensively
used for targeted drug delivery systems due to their unique magnetic properties. Objective:
In this study, it has been aimed to develop a novel targeted 99mTc radiolabeled polymeric drug delivery
system for Gemcitabine (GEM).
Methods: Gemcitabine, an anticancer agent, was encapsulated into polymer nanoparticles (PLGA)
together with iron oxide nanoparticles via double emulsion technique and then labeled with 99mTc.
SPIONs were synthesized by reduction–coprecipitation method and encapsulated with oleic acid
for surface modification. Size distribution and the morphology of the synthesized nanoparticles
were characterized by dynamic light scattering (DLS) and scanning electron microscopy (SEM), respectively.
The radiolabeling yield of SPION-PLGAGEM nanoparticles was determined via Thin
Layer Radio Chromatography (TLRC). Cytotoxicity of GEM loaded SPION-PLGA was investigated
on MDA-MB-231 and MCF7 breast cancer cells in vitro.
Results: SEM images displayed that the average size of the drug-free nanoparticles was 40 nm and
the size of the drug-loaded nanoparticles was 50 nm. The diameter of nanoparticles was determined
as 366.6 nm by DLS, while zeta potential was found as 29 mV. SPION was successfully
coated with PLGA, which was confirmed by FTIR. GEM encapsulation efficiency of SPION-PLGA
was calculated as 4±0.16% by means of HPLC. Radiolabeling yield of SPION-PLGA-GEM
nanoparticles was determined as 97.8±1.75% via TLRC. Cytotoxicity of GEM loaded SPION-PLGA
was investigated on MDA-MB-231 and MCF7 breast cancer cells. SPION-PLGA-GEM
showed high uptake on MCF-7, while the incorporation rate was increased for both cell lines with
external magnetic field application.
Conclusion: 99mTc labeled SPION-PLGA nanoparticles loaded with GEM may overcome some of
the obstacles in anti-cancer drug delivery because of their appropriate size, non-toxic, and superparamagnetic